Hedge funds gained 0.81 per cent in September, according to the Barclay Hedge Fund Index compiled by BarclayHedge.

Year to date, the index is up 4.26 per cent.
 
All but one of Barclay’s 17 hedge fund indices gained ground in September. The Healthcare and Biotechnology Index was up 5.39 per cent, its largest one-month gain since January of 2014.
 
“Although surprises from major central banks whipsawed financial markets, most hedge fund strategies found a path to profitability in September,” says Sol Waksman (pictured), founder and president of BarclayHedge.
 
The Technology Index gained 1.86 per cent, Distressed Securities were up 1.11 per cent, Equity Long Bias gained 0.89 per cent, and Emerging Markets added 0.90 per cent.
 
The only losing sector in September was the Global Macro Index, which was down 0.53 per cent for the month.
 
After three quarters, 12 of Barclay’s hedge fund indices have positive returns for the year. Emerging Markets are up 10.08 per cent, the Event Driven Index has gained 8.56 per cent, Distressed Securities are up 8.31 per cent, the Technology Index has gained 4.64 per cent, and Convertible Arbitrage is up 4.10 per cent.
 
European Equities are down 4.95 per cent year to date, the Global Macro Index has lost 1.40 per cent, Pacific Rim Equities are down 1.36 per cent, and Equity Market Neutral has lost 0.81 per cent.
 
The Barclay Fund of Funds Index gained 0.48 per cent in September, but remains down 1.19 per cent in 2016.